We read with interest the article by Mehta PA et al. 1 in Leukemia (2006) . Although approximately 30% mutations in perforin gene are associated with familial hemophagocytic lymphohistiocytosis (HLH), the perforin A91V substitution has been shown to result only in a reduced natural killer cell and cytotoxic T lymphocytes cytotoxicity. 2 However, recently some reports have linked perforin A91V substitution to confer increased susceptibility to childhood acute lymphoblastic leukemia 3 (ALL) and lymphoma. 4 But Mehta PA et al. 1 could not substantiate this, in a large cohort of B-precursor childhood ALL. This prompted us to study perforin A91V in our population of childhood ALL and lymphoma patients.
The study population included 52 children with de novo childhood ALL, (Pediatric Oncology Group Classification) enrolled at our center over the past 5 years and nine patients with Non-Hodgkin's Lymphoma (NHL). Concurrently, 100 normal voluntary blood donors were also selected to determine the genotype frequencies from the same ethnic population to be used as controls. Genomic DNA was isolated from peripheral blood lymphocytes and the exons 2 and 3 of the perforin (PRF1) coding region was amplified using standard polymerase chain reaction (PCR). PCR products were then purified and sequenced in ABI 3100 DNA sequencer (Applied Biosystems, Foster City, CA, USA).
Surprisingly, we could not find a single patient (ALL or NHL) or control subject with A91V substitution in this ethnic population from the Sultanate of Oman. A review of literature for population frequencies of perforin A91V revealed an allele frequency ranging between 3 and 17% 1, 5 in Caucasian and 0.7% in Afro-American subjects. 1 Over the past 5 years, we have diagnosed (n ¼ 23 cases) and published several cases with HLH, 6 -8 yet none of our HLH patients nor their immediate family members could be shown to have A91V substitution. Thus, it seems that this ethnic population with distinct links to sub-Saharan eastern African states like Zanzibar does not show the perforin A91V substitution.
Given the therapeutic progress achieved over the last few decades, any improvement in the outcome for the majority of patients with acute lymphoblastic leukemia (ALL) is difficult to assess with the size of the trials. Furthermore, the progress in genetics and molecular biology have now led to the identification of subgroups of patients, typically with poor prognosis markers, for whom intensive treatments were rapidly necessary. For both these clinical aspects, there is an increasing need for intergroup cooperation. We suggest here that multicentric molecular studies could be made more feasible, with scientific rigor, by adopting a common methodological strategy to provide results readily available for therapeutic stratification.
From 1994 to 2000, 984 adults (sex ratio M/F ¼ 1.77) patients aged from 15 to 55 years (median age: 33 years) with newly diagnosed ALL (except patients with a previous history of malignant disease) were enrolled in the LALA-94 trial in 50 clinical centers from four countries (France, Belgium, Switzerland and Australia). The study was approved by the Ethics Committee and all patients gave signed informed consent. Molecular biology data from Australian patients were performed separately and not included in this study. In this trial, patient stratification for the second randomization after induction therapy is based on poor prognosis factors defined in adult ALL based on the French ALL protocol. 1, 2 The t(9;22), t(1;19) and t(4;11) translocations and/or their molecular equivalents were considered as independent poor prognosis factors. To do so a group of six laboratories, then extended to 16, combined to identify the four corresponding fusion transcripts (BCR-ABL (m-and M-BCR), E2A-PBX1 and MLL-AF4, respectively) in order to provide data before the second randomization (J35).
Immunophenotype was available for 902 patients, 647 of analyzed ALL patients were B-lineage ALL (72%). The sex ratio (male patients/female patients) of B-lineage ALL patients was 1.38 and the median age was 34 years. Cytogenetic and/or molecular biology evaluation was performed in 863 patients. Overall, 30% of the validated cases had a poor molecular genetic marker and 21% of them were identified only by molecular screening because standard karyotype failed or showed no chromosome abnormalities.
Standardized reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of fusion gene transcripts (BCR-ABL (m-and M-BCR), E2A-PBX1 and MLL-AF4) was performed on 787 patients with ALL, representing more than 80% of the cases enrolled at diagnosis.
The RT-PCR reactions were carried out following in phase 1 (1994-1996) in six laboratories by using published primers sequences 3 and in phase 2 (1996-2000) in 16 laboratories with a common protocol described previously with the European standardized BIOMED-1 primers. 4 Any sample with no amplification of the control genes (ABL or PBGD) was discarded from further analysis. Samples with (i) water instead of RNA and (ii) water instead of reverse transcriptase, were concomitantly examined for each of the reaction units described above to verify that samples were not cross-contaminated. A specificity control of the amplified products was performed either by Southern blot with hybridization of an internal probe or a second PCR reaction with different primers. The quality controls were validated on 720 analyses (91% of tested samples). During the first 3 years of the LALA 94 trials, blind retrospective study was performed between molecular laboratories on a second aliquot of the patient sample. Thus, one of three diagnostic samples (n ¼ 110/300) were retrospectively and blindly verified by a different laboratory in particular to detect any false positive results. Moreover, each positive sample discordant with the karyotype was confirmed by a second analysis on another aliquot. In all, 21% of BCR-ABL þ B-lineage ALL (n ¼ 38), 11% of MLL-AF4 þ (n ¼ 4) and 15% E2A-PBX1 þ B-lineage ALL (n ¼ 4) were diagnosed only with molecular analysis. Generally, the karyotype failed (90% of cases).
Some false negative PCR (8% BCR-ABL þ ALL (n ¼ 14) and 4% E2A-PBX1 (n ¼ 1)) were identified secondary by positive cytogenetic analysis or by retrospective flouroscent in situ hybridization (FISH) because RT-PCR was not carried out or failed. Furthermore, in one case a variant BCR-ABL transcript (b3a3 junction) was reported after confirmation of Phi chromosome by retrospective BCR-ABL FISH. The primers published by Kawasaki et al. 3 were not enable to detect the b3a3 junction leading to a falsely negative RT-PCR. This result contributed to the design of a new primer pair for BCR-ABL amplification (BIOMED-1 protocol). 4 No false positivity was reported. BCR-ABL was the most frequent molecular abnormality in this study (172 cases on 787 analyzed), and accounted for 32% of the B-lineage ALL cases tested (n ¼ 540). Fusion transcripts were detected in 62% of B-lineage ALL patients with age 440 years, among them, 80% were BCR-ABL positive (BCR-ABL þ ). The proportion of BCR-ABL subtype in B-ALL was relatively similar to other studies with 67.6% m-BCR (n ¼ 119), 29.5% M-BCR (n ¼ 49).
5 Few BCR-ABL cases (2.9%; n ¼ 5) showed the two types of BCR-ABL transcripts (m-and M-BCR) with the same intensity of bands on gel. Retrospective FISH analysis showed only one Philadelphia chromosome that corresponds to M-BCR (data not shown) suggesting an alternative splicing process in these cases. The clinical significance of this alternative splicing is actually unknown.
Interestingly, as already known the incidence of BCR ABL positive patients increased with age in contrast to E2A-PBX1 or MLL-AF4 position cases (Po0,001, Figure 1a) . But the expression of the M-BCR transcripts was found with higher incidence in older male patients (sex ratio M/F ¼ 1.8 and median age ¼ 44) (P ¼ 0.0248; age cutoff 42) than the m-BCR, which occurs earlier (sex ratio M/F ¼ 1.3 and median age ¼ 41) with a highest incidence between 35 and 45 years (P ¼ 0.0165). Such data were obtained by a combination of age incidence (Figure 1b ) and sex ratio (Figure 2) . Moreover, the expression of the M-BCR transcripts in the older patients group (42 years old) occurs more frequently at the second semester (P ¼ 0.0346), in contrast to the other four transcripts, which were equally distributed during the year (Supplementary Figure 1) . This trend was present each year over an 8 year period. Immunophenotypic study in BCR-ABL þ patients was similar to literature. Expression of CD36, the thrombospondin receptor, was detected on 21% blast cells BCR-ABL þ (40% on M-BCR (n ¼ 15) with P ¼ 0.013 and 11% on m-BCR (n ¼ 36)) and CD13 was detected on 22.5% blast cells BCR-ABL þ (17% on M-BCR (n ¼ 46) and 28% on m-BCR (n ¼ 113) with Po0.001). Letters to the Editor Table 1 ) were selected for multivariate analysis (Table 1) . At diagnosis, m-BCR is characterised by age 430 years (Po0.0001), CD10 positive (Po0.001) and CD34 positive (P ¼ 0.012) whereas M-BCR occurred second semester (P ¼ 0.04) and with CD36 positive (P ¼ 0.02).
These data suggest that m-BCR and M-BCR breakpoints are probably secondary to two different oncogenic mechanisms and could define a new clinical entity. However, first, this observation was not previously reported in similar large series probably because the age and timing during the year were not available in published data for each transcript (M and m-BCR); 5 second, no statistical analysis of clinical data highlighted difference to date between the two transcripts. This can be explained by, either that the current therapies are not targeted enough, or that the emergence of different breakpoints of BCR-ABL depends on different biological mechanisms. The primary factors that determine preferential breakage are presently unknown. Mechanism of DNA breakage in BCR-ABL gene seems more complicated that this determination by the size of introns or by Alu elements. Other factors, genetic susceptibility and environmental exposure, could be responsible for M-BCR breakpoints. Among the environmental etiological agents, supportive evidence for an infection etiology for M-BCR could be provided by the seasonal variation (second semester) and also by the association to CD36 a human scavenger receptor class B type I. It has been recently demonstrated that an ortholog of CD36 was required for infection of cells by Hepatitis C virus.
Other large prospective studies are warranted to confirm these findings.
Patients (60%) with M-BCR breakpoints express b2a2 (n ¼ 29) whereas 40% have b3a2 (n ¼ 20) transcripts. Interestingly, according to our study, a b2a2 patient is likely to be older than a b3a2 patient (P ¼ 0.04) and that b3a2 is often present in man with B-lineage ALL in contrary to the b2a2 breakpoint (P ¼ 0.001, Figure 2) , suggesting that the two breakpoints of M-BCR may also be of different biological mechanisms but larger cohorts are needed for firm conclusions.
Expression of the MLL-AF4 transcript and E2A-PBX1 transcripts was detected in 6% (36 positive cases) and 4% (26 positive cases) of the B-lineage ALL tested cases. Epidemiological data of MLL-AF4 and E2A-PBX1 are not different to other publications. This study confirms that MLL-AF4 transcript is characterized by the young women (sex ratio M/F ¼ 0.56 and median age ¼ 35) with phenotypic characteristics (CD19 þ , CD10À, CD15 þ and/or CD65 þ ) and that E2A-PBX1 transcript is characterised by the young women (sex ratio M/F ¼ 0.67 and median age ¼ 31) with phenotypic characteristics (CD34À, CD19 þ and CD22 þ ). The clinical outcome of these subpopulations within the LALA94 therapeutic protocol are reported in the accompanying article (N VEY et al.) .
This multicentric organization provided strict guidelines associated with a standard protocol. One clear drawback is the spread of the samples and difficulties to react to the innovation, although we were the first to demonstrate that TEL-AML1 was rarely expressed in adult ALL. 6 Furthermore, this study shows that fusion transcript detection at diagnosis can be carried out easily by molecular biology laboratories near the patient. This proximity allows (i) to avoid that samples from a small number of patients were lost and (ii) that the quality of samples was generally very good.
Futhermore, this multicentric study proved feasible to provide the results readily available for therapeutic stratification by day 35 for most patients. 2 Our study allowed to show that molecular analyses are complementary with classical cytogenetics at diagnosis (i) for confirmation of ALL diagnosis and evaluation of extent of disease, (ii) allowing prognosis stratification for a larger number of patients and (iii) provide targets for molecular residual detection to evaluate therapy efficiency in more than one patient out of three cases with ALL. 7, 8 In clinical practice, we determined that two tests out of three among the FISH, karyotypic analysis and the PCR must be positive to determine the presence of fusion transcript or their cytogenetic equivalent in adult ALL with therapeutic consequences. 9 So, this molecular study allowed (i) to validate the primers for RT-PCR detection of different fusion transcripts of bad prognosis (BIOMED-1), (ii) to clarify the interaction of molecular biology with the care of ALL patients, (iii) by the recruitment of a great number of patients, to bring a statistical proof or trend of a difference in the mechanisms of emergence of M-BCR and m-BCR. 
Figure 2
Sex ratio of different fusion transcripts.
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